- Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drugRoyalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.Fierce Biotech · 3d ago↗ source
- Celldex ends skin disease program after failing phase 2 testA phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to end development in the indication and raising doubts about an upcoming e…Fierce Biotech · 3d ago↗ source
- ‘We’re moving quickly’: Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraiseA rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-known medicine and set its sights on a $50 million fundraise.